passages: 584
passages: document
passages: Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo . We investigated whether 5 to 20mg per week oral methotrexate could slow down disease progression in 44 patients with inclusion body myositis in a randomized double-blind placebo-controlled study over 48 weeks . Mean change of quantitative muscle strength testing sum scores was the primary study outcome measure . Quantitative muscle strength testing sum scores declined in both treatment groups , -0.2 % for methotrexate and -3.4 % for placebo ( 95 % confidence interval = -2.5 % to +9.1 % for difference ) . There were also no differences in manual muscle testing sum scores , activity scale scores and patients ' own assessments after 48 weeks of treatment . Serum creatine kinase activity decreased significantly in the methotrexate group . We conclude that oral methotrexate did not slow down progression of muscle weakness but decreased serum creatine kinase activity .
entities: 585
entities: Intervention_Pharmacological
entities: methotrexate
entities: 586
entities: Intervention_Control
entities: placebo .
entities: 587
entities: Intervention_Pharmacological
entities: methotrexate
entities: 588
entities: Intervention_Pharmacological
entities: methotrexate
entities: 589
entities: Intervention_Control
entities: placebo
entities: 590
entities: Intervention_Pharmacological
entities: methotrexate
entities: 591
entities: Intervention_Pharmacological
entities: methotrexate
entities: 592
entities: Outcome_Physical
entities: weakness progression
entities: 593
entities: Outcome_Physical
entities: disease progression
entities: 594
entities: Outcome_Physical
entities: Mean change of quantitative muscle strength testing sum scores
entities: 595
entities: Outcome_Physical
entities: Quantitative muscle strength testing sum scores
entities: 596
entities: Outcome_Physical
entities: manual muscle testing sum scores , activity scale scores and
entities: 597
entities: Outcome_Other
entities: patients ' own assessments
entities: 598
entities: Outcome_Physical
entities: Serum creatine kinase activity
entities: 599
entities: Outcome_Physical
entities: progression of muscle weakness
entities: 600
entities: Outcome_Physical
entities: serum creatine kinase activity .
entities: 601
entities: Participant_Condition
entities: inclusion body myositis
entities: 602
entities: Participant_Sample-size
entities: 44
entities: 603
entities: Participant_Condition
entities: patients with inclusion body myositis